Table 1 Patient demographics
Findings | Total study | All criteria | HISORt | Japanese | Korean | No criteria met |
|---|---|---|---|---|---|---|
Radiological features | 66 | - | - | - | - | - |
Males (n, %) | 50 (76%) | - | - | - | - | - |
Age (years, mean) | 58 | - | - | - | - | - |
Clinical and radiological features | 55 | 27 (49%) | 30 (55%) | 31 (56%) | 45 (82%) | 9 (16%) |
Males (n, %) | 43 (78%) | 22 (81%) | 25 (83%) | 24 (77%) | 34 (76%) | 8 (%) |
Age (years, mean) | 60 | 61 | 61 | 59 | 60 | 58 |
Presenting symptoms | ||||||
Jaundice | 34 (62%) | 20 (74%) | 22 (73%) | 20 (65%) | 29 (64%) | 5 (56%) |
Weight loss | 36 (65%) | 17 (63%) | 19 (63%) | 19 (61%) | 30 (67%) | 6 (67%) |
Abdominal pain | 37 (67%) | 18 (67%) | 20 (67%) | 20 (65%) | 29 (64%) | 7 (78%) |
IgG4 (g/L, median) | 5.12 | 5.32 | 5.44 | 5.3 | 4.94 | 7.3 |
IgG4 > 2 × ULN (n, %) | 29 (51%) | 20 (74%) | 21 (70%) | 24 (80%) | 24 (53%) | 4 (44%) |
Biochemistry | ||||||
Bilirubin (μmol/L*) | 20 | 35 | 34 | 34 | 21 | 29 |
ALP (U/L*) | 246 | 287 | 287 | 264 | 240 | 296 |
ALT (U/L*) | 74 | 94 | 94 | 81 | 72 | 91 |
AST (U/L*) | 57 | 92 | 92 | 84 | 58 | 46 |
Imaging Modality | ||||||
CT (n, %) | 49 (86%) | 23 (85%) | 26 (87%) | 29 (84%) | 40 (89%) | 8 (89%) |
MRCP (n, %) | 54 (95%) | 27 (100%) | 30 (100%) | 31 (100%) | 44 (98%) | 9 (100%) |
ERCP (n, %) | 35 (61%) | 19 (70%) | 22 (73%) | 19 (61%) | 28 (62%) | 6 (67%) |
Pancreatic parenchymal changes | ||||||
Typical | 24 (44%) | 14 (52%) | 14 (47%) | 14 (45%) | 20 (44%) | 4 (57%) |
Diffuse | 5 (9%) | 3 (19%) | 4 (13%) | 3 (10%) | 4 (9%) | 0 (0%) |
Multifocal | 23 (42%) | 11 (41%) | 11 (37%) | 13 (42%) | 18 (40%) | 5 (56%) |
Rim | ||||||
Atypical | 18 (33%) | 5 (19%) | 7 (23%) | 9 (29%) | 16 (36%) | 2 (22%) |
Focal | 5 (9%) | 4 (15%) | 5 (17%) | 4 (13%) | 5 (11%) | 0 (0%) |
Atrophic | ||||||
Treatment | ||||||
Steroids | 34 (62%) | 19 (70%) | 21 (70%) | 22 (71%) | 31 (69%) | 3 (33%) |
ERCP + Biliary stent | 27 (49%) | 15 (56%) | 17 (57%) | 15 (48%) | 23 (51%) | 4 (44%) |
Steroids and biliary stent | 16 (29%) | 10 (37%) | 12 (40%) | 10 (32%) | 16 (36%) | 0 (0%) |